Jupiter Neurosciences, Inc. Common Stock
Here’s whether Jupiter Neurosciences, Inc. Common Stock (JUNS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-6.62% over 10 days); RSI 26 — oversold; weak 1-year return of -58.2%; 3-month momentum negative (-60.2%); rising volume on a downtrend (distribution, 2.98x avg). Currently 92.9% off its 52-week high. Score: -7/7.
JUNS is trading below its 200-day MA ($0.95) — a key warning sign the longer-term trend is under pressure. An RSI of 26.2 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -58.2% compares to +27.9% for SPY (trailed the market by 86.1%). The current 92.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.